Related references
Note: Only part of the references are listed.PCSK-9 Inhibitors in a Real-World Setting and a Comparison Between Alirocumab and Evolocumab in Heterozygous FH Patients
Jose Juan Ceballos-Macias et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Jan Boren et al.
EUROPEAN HEART JOURNAL (2020)
Familial hypercholesterolemia: A complex genetic disease with variable phenotypes
Maria Donata Di Taranto et al.
EUROPEAN JOURNAL OF MEDICAL GENETICS (2020)
Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience
Giuseppe Mandraffino et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2020)
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia
Raul D. Santos et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Changes in carotid stiffness in patients with familial hypercholesterolemia treated with Evolocumab (R): A prospective cohort study
Matteo Nicola D. Di Minno et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)
Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR
Unai Galicia-Garcia et al.
SCIENTIFIC REPORTS (2020)
Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease A Systematic Review and Meta-Analysis
Pengwei Hu et al.
CIRCULATION (2020)
Endothelial function improvement in patients with familial hypercholesterolemia receiving PCSK-9 inhibitors on top of maximally tolerated lipid lowering therapy
Alessandro Di Minno et al.
THROMBOSIS RESEARCH (2020)
Lipid profile and genetic status in a familial hypercholesterolemia pediatric population: exploring the LDL/HDL ratio
Maria Donata Di Taranto et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2019)
Proprotein convertase subtilisin/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications
Dennis V. Cokkinos et al.
ARCHIVES OF CARDIOVASCULAR DISEASES (2019)
Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry
P. Barton Duell et al.
ATHEROSCLEROSIS (2019)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary
Scott M. Grundy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab
Aurelie Thedrez et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study
Manuela Casula et al.
ATHEROSCLEROSIS (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia
Joep C. Defesche et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2017)
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Robert P. Giugliano et al.
LANCET (2017)
Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia
Paolo Rubba et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2017)
Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia
Maria Donata Di Taranto et al.
SCIENTIFIC REPORTS (2017)
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN)
Maurizio Averna et al.
ATHEROSCLEROSIS SUPPLEMENTS (2017)
Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care
Valeria Guglielmi et al.
ATHEROSCLEROSIS (2017)
Association between Lp (a) and atherosclerosis in menopausal women without metabolic syndrome
Marco Gentile et al.
BIOMARKERS IN MEDICINE (2016)
Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia
Ioanna Gouni-Berthold et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano et al.
EUROPEAN HEART JOURNAL (2016)
Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia
Amit V. Khera et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2016)
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
Erik S. Stroes et al.
EUROPEAN HEART JOURNAL (2015)
Association of USF1 and APOA5 polymorphisms with familial combined hyperlipidemia in an Italian population
Maria Donata Di Taranto et al.
MOLECULAR AND CELLULAR PROBES (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The novel variant p.Ser465Leu in the PCSK9 gene does not account for the decreased LDLR activity in members of a FH family
Anna Ruotolo et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2014)
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Erik Stroes et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
An improved method on stimulated T-lymphocytes to functionally characterize novel and known LDLR mutations
Maria Romano et al.
JOURNAL OF LIPID RESEARCH (2011)
Ezetimibe-associated adverse effects: what the clinician needs to know
M. Florentin et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Share Paper
